Japanese scientists will test the use of human-induced pluripotent stem cells (iPS) to treat spinal cord injuries, a health ministry panel that approved the research project said.
Activist hedge fund Starboard Value LP asked a proxy solicitor to probe the level of support among Bristol-Myers Squibb Co. shareholders for the U.S. drug maker’s $74 billion deal to buy Celgene Corp., people familiar with the matter said.
Nektar Therapeutics said some patients with advanced bladder cancer treated with a combination of the company’s experimental treatment and Bristol-Myers Squibb’s immunotherapy Opdivo showed signs of tumor reduction in an early-stage study.
Patients who discharge themselves from the hospital against medical advice are twice as likely to be back within 30 days as those who leave when doctors say they are ready, a large U.S. study finds.
The number of push-ups a man can do in the doctor’s office may be a good predictor of his risk of developing heart disease in the coming years, new research suggests.
German drugmaker Bayer acquired all rights the company does not already own in Vitrakvi, a drug against a variety of cancers driven by a rare genetic mutation, from Eli Lilly’s Loxo Oncology.
The U.S. Centers for Medicare & Medicaid Services proposed Medicare coverage of approved CAR-T cell therapies that use the patient’s immune system to fight cancer.
At the American Society of Clinical Oncology 2019 Genitourinary Cancers Symposium (ASCO GU), companies have showcased more clinical data in presentations for prostate cancer treatment.
Merck & Co. is launching three late-stage studies for the cancer immunotherapy Keytruda as a combo treatment for prostate cancer after the drug showed anti-tumor activity in an early-stage trial.
Ireland’s Teckro, which makes software that allows physicians to take part in drug development trials from mobile devices, has won $25 million in financial backing from investors as the company hatches longer-term plans for a stock market listing.